Under our immuno-oncology collaboration with GlaxoSmithKline (GSK) we have granted exclusive rights to GSK to develop and commercialize the following AnaptysBio-generated antibody product candidates:
- Anti-PD-1 Monospecific Antagonist Antibody (Dostarlimab, GSK4057190A): BLA and MAA filings accepted by FDA and EMA, respectively, in Q1 2020, for the treatment of advanced or recurrent deficient mismatch repair (dMMR) endometrial cancer; BLA and MAA filings anticipated in H1 2021 for second indication – dMMR pan-tumor;
- Anti-TIM-3 Monospecific Antagonist Antibody (Cobolomab, GSK4069889A): Dose escalation completed in Phase 1, combination trial with TSR-042 has been initiated;
- Anti-LAG-3 Monospecific Antagonist Antibody (GSK4074386): Phase 1 trial initiated, combination trial with TSR-042 has been initiated; and
- Anti-PD-1/LAG-3 Bispecific Antagonist Antibody: lead candidate identified, IND-enabling studies on-going.
To access scientific publications on this topic, please click here.
Bristol-Myers Squibb Partnership
Under our collaboration with Bristol-Myers Squibb (BMS) we developed therapeutic antibodies against multiple targets. We granted BMS the option to obtain worldwide commercial rights to antibodies generated against each of the targets under the agreement, which option was triggered on a target-by-target basis by our delivery of antibodies meeting certain pre-specified parameters pertaining to each target under collaboration. BMS is currently advancing two AnaptysBio-generated anti-inflammatory antibody programs, and has initiated a Phase 1 trial for one of these two antibodies known as CC-90006, a PD-1 agonist antibody, which is indicated for psoriasis.